Skip to main content

Advertisement

Table 1 Diagnostic performance of urinary CXCR3 chemokine proteins

From: Developing renal allograft surveillance strategies – urinary biomarkers of cellular rejection

Biomarker     Acute cellular rejection g   Subclinical rejection  
CXCL9 Population Study Design n a, b AUC Sensitivity Specificity Ref AUC Sensitivity Specificity Ref
  Multi-center c Prospective, observational cohort 280 0.86 0.87 0.82 26 Subclinical group too small for AUC
  Single center Prospective, observational cohort 69 NR 0.93 0.89 44 Subclinical group too small for AUC e
  Single center Case control 125 0.87 0.86 0.80 45 Subclinical group too small for AUC
  Two centers Case control 88      0.78 0.86 0.64 27
  Single center Case control 113 0.92 0.85 0.90 42     
  Single center Case control 99 NR 0.80 0.94 43     
  Single center Case control 201 0.90 0.84 0.83 46     
  Single center f Case control 213 0.91 0.90 0.84 47     
CXCL10 Population Study Design n a, b AUC Sensitivity Specificity Ref AUC Sensitivity Specificity Ref
  Multi-center c Prospective, observational cohort 280 0.77 0.74 0.86 26 Subclinical group too small for AUC
  Single center Prospective, observational cohort 213 0.74 0.63 0.80 25 0.69 0.61 0.72 25
  Two centers Case control 88      0.79 0.68 0.90 27
  Single center Case control 91 0.84 0.78 0.59 28 0.85 0.73 0.73 28
  Single center d Case control 51 0.88 0.77 0.60 52 0.81 0.59 0.67 52
  Single center Case control 54      0.77 e 0.62 0.95 48
  Single center c Case control 125 0.83 0.80 0.76 45 Subclinical group too small for AUC
  Single center Case control 113 0.93 0.89 0.81 42     
  Single center Case control 99 NR 0.86 0.91 43     
  Single center Case control 201 0.81 0.65 0.97 46     
  Single center f Case control 213 0.80 0.70 0.76 47     
  1. a Numbers of patients (not urine numbers), some studies are confounded with repeated measures; b Numbers in the AUC analysis, not the overall study population; c Pediatric population included; d Pediatric population only; e Subclinical refers to the AUC 4-5 days prior to clinical rejection for these studies; f Rabant et al. performed a prospective observational study of patients with indication biopsies – the data reported here are for the TCMR sub-group analysis; g Rejection is scored by the Banff criteria, but the definitions used vary by study. NR not reported